Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective StudyAdam S. Kittai, Philip A. Thompson, John C. Byrd et al.|Journal of Clinical Oncology|2024Cited by 43
CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insightsNaveen Pemmaraju, Marina Konopleva, Joseph D. Khoury et al.|Leukemia Research|2022Cited by 18
ALL-808 Very Promising Results of the Dose Dense (D-D) Mini-Hyper-CVD-Inotuzumab-Blinatumomab Phase 2 Trial in Patients with Relapsed-Refractory Acute Lymphoblastic LeukemiaElias Jabbour, Hagop Kantarjian, Fadi Haddad et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 7
Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular FeaturesWalid Macaron, Nicholas J. Short, Farhad Ravandi et al.|Blood|2024Cited by 5
Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic PhaseFadi Haddad, Hagop Kantarjian, Sara Dellasala et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 4